miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting
AML patients with miR-182 promoter hypermethylation have better outcomes. miR-182 promoter methylation is a predictive biomarker for AZA + VEN-treated AML patients.
Authors
- Yigang Yuan
- Zihan Lin (ORCID: https://orcid.org/0000-0002-1912-0729)
- Min Zhao (ORCID: https://orcid.org/0000-0001-5498-3434)
- Liuzhi Shi (ORCID: https://orcid.org/0000-0001-9484-8616)
- Bei Ge (ORCID: https://orcid.org/0000-0002-0771-1935)
- Haige Ye (ORCID: https://orcid.org/0000-0002-2980-3806)
- Shenmeng Gao (ORCID: https://orcid.org/0000-0003-1223-4325)
- Danyang Li (ORCID: https://orcid.org/0009-0007-9722-8798)
- Na Wang (ORCID: https://orcid.org/0000-0002-9776-7683)
- Cai Yue
- Min Li (ORCID: https://orcid.org/0000-0003-1350-9909)
- Yilan Xu
- Meng Chen (ORCID: https://orcid.org/0000-0003-4141-7999)
Institutions
- Ningbo University (CN)
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Affiliated Eye Hospital of Wenzhou Medical College (CN)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1186/s13148-025-01823-1
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province